If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> A SUPPLEMENT TO NEUROLOGY REVIEWS<br /> Clinical Reviews of JCV and PML<br /> JULY 2011<br /> Understanding the Complexities of<br /> JCV and PML<br /> An Overview of<br /> JC Virus and<br /> Progressive Multifocal<br /> Leukoencephalopathy<br /> The Epidemiology of<br /> Progressive Multifocal<br /> Leukoencephalopathy<br /> Progressive Multifocal<br /> Leukoencephalopathy:<br /> Survival Statistics<br /> Supported by Biogen Idec<br /> Understanding the<br /> Complexities of<br /> JCV and PML<br /> SUPPLEMENT EDITOR<br /> Mark Gudesblatt, MD<br /> FACULTY<br /> Mark Gudesblatt, MD<br /> John F. Foley, MD<br /> Moti L. Chapagain, PhD<br /> CONTENTS<br /> An Overview of JC Virus<br /> and Progressive Multifocal<br /> Leukoencephalopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3<br /> Mark Gudesblatt, MD<br /> The Epidemiology of<br /> Progressive Multifocal<br /> Leukoencephalopathy . . . . . . . . . . . . . . . .<a title="Biogen digital.pdf page 1" href="http://viewer.zmags.com/publication/f84595ef?page=1"> A SUPPLEMENT TO NEUROLOGY REVIEWS Clinical Rev</a> <a title="Biogen digital.pdf page 2" href="http://viewer.zmags.com/publication/f84595ef?page=2"> Understanding the Complexities of JCV and PML </a> <a title="Biogen digital.pdf page 3" href="http://viewer.zmags.com/publication/f84595ef?page=3"> An Overview of JC Virus and Progressive Multifoca</a> <a title="Biogen digital.pdf page 4" href="http://viewer.zmags.com/publication/f84595ef?page=4"> rus of the genus Papovaviridae that was first iso</a> <a title="Biogen digital.pdf page 5" href="http://viewer.zmags.com/publication/f84595ef?page=5"> cation. Although PML is generally considered to b</a> <a title="Biogen digital.pdf page 6" href="http://viewer.zmags.com/publication/f84595ef?page=6"> VP1 capsid protein are associated with the de- ve</a> <a title="Biogen digital.pdf page 7" href="http://viewer.zmags.com/publication/f84595ef?page=7"> JCV exposure than those who are not immu- nocompe</a> <a title="Biogen digital.pdf page 8" href="http://viewer.zmags.com/publication/f84595ef?page=8"> References 1. Tan CS, Koralnik IJ. Progressi</a> <a title="Biogen digital.pdf page 9" href="http://viewer.zmags.com/publication/f84595ef?page=9"> 39. Weber F, Goldmann C, Krämer M, et al. Ce</a> <a title="Biogen digital.pdf page 10" href="http://viewer.zmags.com/publication/f84595ef?page=10"> The Epidemiology of Progressive Multifocal Leukoe</a> <a title="Biogen digital.pdf page 11" href="http://viewer.zmags.com/publication/f84595ef?page=11"> ticularly oligodendrocytes. PML is now known to b</a> <a title="Biogen digital.pdf page 12" href="http://viewer.zmags.com/publication/f84595ef?page=12"> diseases, which represent an autoimmune in- </a> <a title="Biogen digital.pdf page 13" href="http://viewer.zmags.com/publication/f84595ef?page=13"> tive therapies appear to exert some change on the</a> <a title="Biogen digital.pdf page 14" href="http://viewer.zmags.com/publication/f84595ef?page=14"> tainment of JCV in the CNS as well as influ- ence</a> <a title="Biogen digital.pdf page 15" href="http://viewer.zmags.com/publication/f84595ef?page=15"> For example, CSF assays of JCV DNA have cor- rela</a> <a title="Biogen digital.pdf page 16" href="http://viewer.zmags.com/publication/f84595ef?page=16"> 10. Chapagain ML, Nerurkar VR. Human poly</a> <a title="Biogen digital.pdf page 17" href="http://viewer.zmags.com/publication/f84595ef?page=17"> Progressive Multifocal Leukoencephalopathy: Survi</a> <a title="Biogen digital.pdf page 18" href="http://viewer.zmags.com/publication/f84595ef?page=18"> TABLE 1 Common clinical features of AIDS-associa</a> <a title="Biogen digital.pdf page 19" href="http://viewer.zmags.com/publication/f84595ef?page=19"> TABLE 2 Different forms of PML Classic PML PML</a> <a title="Biogen digital.pdf page 20" href="http://viewer.zmags.com/publication/f84595ef?page=20"> TABLE 3 Summary of agents predisposing to PML Ag</a> <a title="Biogen digital.pdf page 21" href="http://viewer.zmags.com/publication/f84595ef?page=21"> characteristic brain changes on magnetic res- ona</a> <a title="Biogen digital.pdf page 22" href="http://viewer.zmags.com/publication/f84595ef?page=22"> 88% (22 of 25) sera from natalizumab-associ- ated</a> <a title="Biogen digital.pdf page 23" href="http://viewer.zmags.com/publication/f84595ef?page=23"> with HIV-associated PML, recent studies sug- gest</a> <a title="Biogen digital.pdf page 24" href="http://viewer.zmags.com/publication/f84595ef?page=24"> The marked difference in survival in that mul</a> <a title="Biogen digital.pdf page 25" href="http://viewer.zmags.com/publication/f84595ef?page=25"> Natalizumab, the first monoclonal anti- bo</a> <a title="Biogen digital.pdf page 26" href="http://viewer.zmags.com/publication/f84595ef?page=26"> was employed, the patient developed PML seve</a> <a title="Biogen digital.pdf page 27" href="http://viewer.zmags.com/publication/f84595ef?page=27"> 22. Lebwohl M, Tyring SK, Hamilton TK, et al. </a> <a title="Biogen digital.pdf page 28" href="http://viewer.zmags.com/publication/f84595ef?page=28"> </a>